NASDAQ: BNOXBionomics Limited Stock
$0.97+0.02 (+2.11%)
Updated Apr 25, 2024
BNOX Price
$0.97
Fair Value Price
$0.75
Market Cap
$11.16M
52 Week Low
$0.87
52 Week High
$6.41
P/E
0.03x
P/B
0.58x
P/S
815.06x
PEG
0x
Dividend Yield
N/A
Revenue
$14.50k
Earnings
-$21.09M
Gross Margin
100%
Operating Margin
-140,487.81%
Profit Margin
-140,642.5%
Debt to Equity
0.34
Operating Cash Flow
-$18M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BNOX Overview
Bionomics Ltd is a clinical-stage biopharmaceutical company focused on drug candidates to transform the lives of patients suffering from serious central nervous system disorders. The company's lead candidate, BNC210, is a treatment for Social Anxiety Disorder and Post-Traumatic Stress Disorder. Bionomics was incorporated in 1996 and is based in Eastwood, Australia.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BNOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BNOX ($0.97) is overvalued by 29.32% relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BNOX ($0.97) is not significantly undervalued (29.32%) relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BNOX ($0.97) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BNOX due diligence checks available for Premium users.
Be the first to know about important BNOX news, forecast changes, insider trades & much more!
BNOX News
Valuation
BNOX fair value
Fair Value of BNOX stock based on Discounted Cash Flow (DCF)
Price
$0.97
Fair Value
$0.75
Overvalued by
29.85%
BNOX ($0.97) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BNOX ($0.97) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BNOX ($0.97) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BNOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.03x
Industry
15.41x
Market
40.97x
BNOX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BNOX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BNOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
5.8x
BNOX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BNOX price to earnings growth (PEG)
For valuing profitable companies with growth potential
BNOX is good value based... subscribe to Premium to read more.
PEG Value Valuation
BNOX's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BNOX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BNOX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.4M
Liabilities
$6.7M
Debt to equity
0.34
BNOX's short-term assets ($11.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BNOX's short-term assets ($11.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BNOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BNOX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BNOX vs Biotech Stocks
Bionomics Limited Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.